Ketoconazole in Taiwanese castration-resistant prostate cancer patients: Evaluation of response rates, durations, and predictors

Urological Science

Volumn 23, Issue 2, 2012, Pages 48-51

  Chiang, Bing Juin ^a   Pu, Yeong Shiau ^a   Yu, Hong Jeng ^a   Huang, Chao Yuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Castration resistant prostate cancer; Hormone manipulation; Ketoconazole; Prostate cancer

Indexed keywords

KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HUMAN; LIVER FUNCTION; MALE; MEDICAL RECORD REVIEW; NAUSEA; ORCHIECTOMY; PRIORITY JOURNAL; SIDE EFFECT; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; VERTIGO;

EID: 84862663070     PISSN: 18795226     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urols.2012.04.004     Document Type: Article

References (18)

1. Reid A.H., Attard G., Barrie E., de Bono J.S. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008, 5:610-620.
2. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987, 317:812-818.
3. Small E.J., Halabi S., Dawson N.A., Stadler W.M., Rini B.I., Picus J., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004, 22:1025-1033.
4. Harris K.A., Weinberg V., Bok R.A., Kakefuda M., Small E.J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002, 168:542-545.
5. Heidenreich A., Bolla M., Joniau S., Mason M.D., Matveev V., Mottet N., et al. Guidelines on prostate cancer. European Association of Urology 2010.
6. Bubley G.J., Carducci M., Dahut W., Dawson N., Daliani D., Eisenberger M. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17:3461-3467.
7. Smith J.A., Lange P.H., Janknegt R.A., Abbou C.C., deGery A. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol 1997, 157:1329-1334.
8. Kelly W.K., Curley T., Leibretz C., Dnistrian A., Schwartz M., Scher H.I. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995, 13:2208-2213.
9. Small E.J., McMillan A., Meyer M., Chen L., Slichenmyer W.J., Lenehan P.F., et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol 2001, 19:1304-1311.
10. Scholz M., Jennrich R., Strum S., Brosman S., Johnson H., Lam R., et al. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 2005, 173:1947-1952.
11. Small E.J., Baron A.D., Fippin L., Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997, 157:1204-1207.
12. Millikan R., Baez L., Banerjee T., Wade J., Edwards K., Winn R., et al. Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urol Oncol 2001, 6:111-115.
13. Wilkinson S., Chodak G. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. Eur Urol 2004, 45:581-584.
14. Nakabayashi M., Xie W., Regan M.M., Jackman D.M., Kantoff P.W., Oh W.K. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 2006, 107:975-981.
15. Glass A.R. Ketoconazole-induced stimulation of gonadotropin output in men: basis for a potential test of gonadotropin reserve. J Clin Endocrinol Metab 1986, 63:1121-1125.
16. Oka H., Negoro H., Sugino Y., Iwamura H., Moroi S., Kawakita M. Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment. Hinyokika Kiyo. 2003, 49:521-525. [in Japanese].
17. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
18. Womble P.R., Vanveldhuizen P.J., Nisbet A.A., Reed G.A., Thrasher J.B., Holzbeierlein J.M. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol 2011, 186:882-887.